Most pharmaceutical businesses are slow-moving by nature due to the lengthy amount of time it takes to develop a new medicine ...

AbbVie (ABBV) Company Description: AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women’s health and ...

At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...

The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.

Migraines affect nearly 40 million people in the U.S. alone, and symptoms like headache, nausea and light sensitivity can often disrupt attendance and performance at work and school. In fact ...

AbbVie (ABBV) Company Description: AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women’s health and ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of AbbVie (NYSE:ABBV) with a Outperform ...

AbbVie's successful pivot away from Humira isn't the only reason retail investors should consider adding the shares to their portfolios. The company estimates that in 2026, its oncology portfolio ...

AbbVie’s ABBV stock declined almost 11% in ... while also signing some early-stage deals in oncology and neuroscience areas. In 2024, it acquired smaller biotechs like Landos Biopharma and ...

The data had already caused a stir ahead of that year’s American Society for Clinical Oncology (ASCO), and hungry for shiny-looking drug candidates to stuff its pipeline, AbbVie’s CEO Richard ...

AbbVie will clearly fight to keep its top-selling Humira (adalimumab) anti-inflammatory drug on the market for as long as possible – but it also has one eye on a possible successor that is ...